- Sector: Research
- Region: Yorkshire and the Humber
Fishing for growth
Benchmark is a company that likes to live up to its name, setting an industry standard for technology-rich products that support aquaculture producers around the world. Over the past five years, it has invested more than £40m in research and development (R&D) in a pioneering effort to apply gene editing to aquaculture, and it now has 70 products in its development pipeline.
"Our aim is to address some of the main challenges facing the industry, such as disease, quality, profitability and sustainability," explains Chief Executive Officer Malcolm Pye. "We have retained our position in the market by developing strong relationships with our clients and by staying at the forefront of technology. Our technology leadership is the result of our ability to attract top scientists, our R&D investment and our acquisition strategy."
Having started out as a consulting-led firm with three founding partners in 2000, Benchmark has transformed itself into an international group employing close to 1,000 staff, comprising 42 nationalities and with total revenues of £140m. The company now has more than 1,400 customers across 70 countries.
"There are two factors that have been key to our sustained growth," explains Malcolm. "Firstly, our vision to become a global leader in the areas of genetics, advanced nutrition and health. The second key factor has been access to capital, which was enabled through our listing on AIM in 2013 and without which we would not have been able to execute our strategy."
The company prides itself on both investment and patience, as can be seen with Ectosan, which is the result of more than a decade of research and capital investment. "The launch of this new product exemplifies our mission and core competencies," says Malcolm. "It addresses one of the main disease challenges in aquaculture today in a sustainable way."